As things stand now, there are bound to be allegations of improper encroachment of indications since everyone knows the two drugs are medically equivalent. I think the solution I proposed would be simpler and cleaner for both companies, but I don’t actually expect it to happen.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”